Last reviewed · How we verify

Phenylephrine 1.0%/ Ketorolac 0.3% — Competitive Intelligence Brief

Phenylephrine 1.0%/ Ketorolac 0.3% (Phenylephrine 1.0%/ Ketorolac 0.3%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination ophthalmic decongestant and NSAID. Area: Ophthalmology.

marketed Combination ophthalmic decongestant and NSAID Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Phenylephrine 1.0%/ Ketorolac 0.3% (Phenylephrine 1.0%/ Ketorolac 0.3%) — University of Florida. This combination ophthalmic drop uses phenylephrine to constrict blood vessels and reduce redness while ketorolac provides anti-inflammatory and analgesic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Phenylephrine 1.0%/ Ketorolac 0.3% TARGET Phenylephrine 1.0%/ Ketorolac 0.3% University of Florida marketed Combination ophthalmic decongestant and NSAID Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination ophthalmic decongestant and NSAID class)

  1. University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phenylephrine 1.0%/ Ketorolac 0.3% — Competitive Intelligence Brief. https://druglandscape.com/ci/phenylephrine-1-0-ketorolac-0-3. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: